AZD-1222

Investigational

Approval Year

Substance Class	Structurally Diverse
Source Materials Class	ORGANISM
Source Materials Type	VIRUS
Source Materials State	LIVE ATTENUATED GENETICALLY MODIFIED
Organism Family	Adenoviridae
Organism Genus	Mastadenovirus
Organism Species	simian mastadenovirus e
Author	NONE
Infraspecific Type	RECOMBINANT VECTOR
Infraspecific Name	ChAdOx1 nCoV-19
Part	WHOLE
Record UNII	B5S3K2V0G8
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

AZD-1222

Code

English

DNA (RECOMBINANT SIMIAN ADENOVIRUS OX1 .DELTA.E1E3 VECTOR HUMAN CYTOMEGALOVIRUS PROMOTER PLUS HUMAN TISSUE PLASMINOGEN ACTIVATOR SIGNAL PEPTIDE FUSION PROTEIN WITH SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 ISOLATE WUHAN-HU-1 SPIKE GLYCOPROTEIN CODO

Systematic Name

English

AZD1222

Code

English

COVISHIELD

Brand Name

English

OXFORD-ASTRAZENECA COVID VACCINE

Common Name

English

Showing 1 to 5 of 6 entries

Previous1 2Next

Show entries

Code System

Code

Type

Description

SMS_ID

300000016760

PRIMARY

WIKIPEDIA

Oxford–AstraZeneca COVID-19 vaccine

PRIMARY

CAS

2420395-83-9

PRIMARY

NCI_THESAURUS

C173021

PRIMARY

DRUG BANK

DB15656

PRIMARY

Showing 1 to 5 of 6 entries

Previous1 2Next

Show entries

Related Record

Type

Details


					RX3FFK5JG9

AZD-1222 SARS-COV-2 SPIKE PROTEIN VACCINE ANTIGEN

EXPRESSED PROTEIN->VECTOR

Amount:


					D7K5AF7CUB

AZD-1222 SARS-COV-2 SPIKE PREPROTEIN VACCINE ANTIGEN

EXPRESSED PROTEIN->VECTOR

Amount:


					B6L4N5Z4GH

SARS-COV2

TARGET ORGANISM->VACCINE ANTIGEN

Comments:

One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen (n=8,895) showed 62% efficacy when given as two full doses at least one month apart. The combined analysis from both dosing regimens (n=11,636) resulted in an average efficacy of 70%. no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine. There were a total of 131 COVID-19 cases in the interim analysis

Qualification:

EFFICACY

Amount:

70 % [62 to 90] (average)

Showing 1 to 3 of 3 entries

Previous1Next

Show entries

Related Record

Type

Details


					B5S3K2V0G8

AZD-1222

ACTIVE MOIETY

Amount:

Showing 1 to 1 of 1 entries

Previous1Next

Structural Modifications

Show entries

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
GENE DELETION					CHIMPANZEE ADENOVIRUS E1 GENE	SK3BO0EB8B
INSERTED GENE EXPRESSION VECTOR		SITE_SPECIFIC			UNSPECIFIED SUBSTANCE	eaa5aa8e (not in database)

Showing 1 to 2 of 2 entries

Previous1Next